RETINALGENIX HIGH-RESOLUTION RETINAL IMAGING - HOME & REMOTE MONITORING - DNA/RNA GPS PHARMACOGENETIC MAPPING - DIAGNOSTIC TESTING & THERAPEUTICS TESTING DRUG VALIDATION & THERAPEUTICS Trademark
Trademark Overview
On Wednesday, December 20, 2023, a trademark application was filed for RETINALGENIX HIGH-RESOLUTION RETINAL IMAGING - HOME & REMOTE MONITORING - DNA/RNA GPS PHARMACOGENETIC MAPPING - DIAGNOSTIC TESTING & THERAPEUTICS TESTING DRUG VALIDATION & THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the RETINALGENIX HIGH-RESOLUTION RETINAL IMAGING - HOME & REMOTE MONITORING - DNA/RNA GPS PHARMACOGENETIC MAPPING - DIAGNOSTIC TESTING & THERAPEUTICS TESTING DRUG VALIDATION & THERAPEUTICS trademark a serial number of 98324339. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, May 31, 2024. This trademark is owned by Retinalgenix Technologies Inc.. The RETINALGENIX HIGH-RESOLUTION RETINAL IMAGING - HOME & REMOTE MONITORING - DNA/RNA GPS PHARMACOGENETIC MAPPING - DIAGNOSTIC TESTING & THERAPEUTICS TESTING DRUG VALIDATION & THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
High-Resolution retinal imaging; Home and remote monitoring; DNA/RNA GPS pharmacogenetic mapping; Diagnostic testing and therapeutics testing: Drug validation and therapeutics
General Information
| Serial Number | 98324339 |
| Word Mark | RETINALGENIX HIGH-RESOLUTION RETINAL IMAGING - HOME & REMOTE MONITORING - DNA/RNA GPS PHARMACOGENETIC MAPPING - DIAGNOSTIC TESTING & THERAPEUTICS TESTING DRUG VALIDATION & THERAPEUTICS |
| Filing Date | Wednesday, December 20, 2023 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Friday, May 31, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Description of Mark | The mark consists of the word RetinalGeniX written in stylized font above the words High-Resolution Retinal Imaging - Home & Remote Monitoring - DNA/RNA GPS Pharmacogenetic Mapping - Diagnostic Testing & Therapeutics Testing Drug Validation & Therapeutics. All of this is written over a background with different shaped hexagons. |
| Pseudo Mark | RETINAL GENICS HIGH RESOLUTION RETINAL IMAGING HOME AND REMOTE MONITORING DNA RNA GPS PHARMACOGENETIC MAPPING DIAGNOSTIC TESTING AND THERAPEUTICS TESTING DRUG VALIDATION AND THERAPEUTICS |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | High-Resolution retinal imaging; Home and remote monitoring; DNA/RNA GPS pharmacogenetic mapping; Diagnostic testing and therapeutics testing: Drug validation and therapeutics |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, December 20, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Retinalgenix Technologies Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Petaluma, CA 94954 |
Trademark Events
| Event Date | Event Description |
| Wednesday, December 20, 2023 | NEW APPLICATION ENTERED |
| Monday, April 1, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, May 15, 2024 | ASSIGNED TO EXAMINER |
| Friday, May 31, 2024 | NON-FINAL ACTION E-MAILED |
| Tuesday, September 3, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Tuesday, September 3, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, May 31, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, May 31, 2024 | NON-FINAL ACTION WRITTEN |
